Amneal Pharmaceuticals, Inc. AMRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $78M+57.3% | $49.57M+173% | $18.13M-49.1% | $35.61M+44.7% | $24.62M+219% | ||
| $8.82M+7.5% | $8.2M-0.2% | $8.22M-0.7% | $8.27M+14.0% | $7.26M+0.7% | ||
| $3.89M+4.7% | $3.72M-26.1% | $5.03M-26.8% | $6.88M+0.9% | $6.81M-0.1% | ||
| -$44.01M-526% | $10.34M-86.7% | $77.61M+44.4% | $53.76M+354% | -$21.15M-174% | ||
| $54.96M+172% | $20.18M-34.5% | $30.81M+35.3% | $22.78M+71.7% | $13.26M-74.5% | ||
| -$124.58M-771% | $18.58M-73.4% | $69.75M+52.9% | $45.62M+141% | -$112.63M-270% | ||
| $13.4M— | $0-100% | $10.16M+6.9% | $9.5M+1,752% | $513K— | ||
| -$1.49M-28.4% | -$1.16M+12.4% | -$1.32M-40.4% | -$941K+28.3% | -$1.31M+47.5% | ||
| -$3.51M— | —— | -$31.37M— | —— | $0— | ||
| -$26.74M-121% | $130.32M+10.0% | $118.45M+41.3% | $83.82M+1,031% | $7.41M-93.7% | ||
| $8.18M-62.5% | $21.77M+77.0% | $12.3M-46.1% | $22.83M+73.5% | $13.16M-13.2% | ||
| $7.85M+162% | $3M-59.5% | $7.41M+724% | $900K-78.6% | $4.2M+600% | ||
| $0— | —— | —— | $855K+63.2% | $524K— | ||
| -$21.71M+52.2% | -$45.45M-102% | -$22.46M+15.4% | -$26.55M-49.2% | -$17.8M-10.8% | ||
| $134.67M-94.6% | $2.48B— | $0-100% | $218M— | $0+100% | ||
| $38K-93.1% | $553K-15.3% | $653K-4.7% | $685K+893% | $69K-54.3% | ||
| $44.31M+13,702% | $321K+149% | $129K-31.7% | $189K-99.1% | $21.64M+5,491% | ||
| $1.98M— | —— | $73.23M+4,096% | $1.75M— | $0— | ||
| -$59.06M-484% | -$10.12M— | —— | -$41.69M-6.4% | -$39.17M+36.0% | ||
| -$1.02M-389% | -$209K+69.9% | -$694K-126% | -$307K+34.7% | -$470K+36.5% | ||
| -$108.53M-246% | $74.53M-51.8% | $154.74M+913% | $15.28M+131% | -$50.03M-225% | ||
| $56.45M+36.3% | $41.4M-5.5% | $43.8M-22.2% | $56.32M0.0% | $56.32M-7.1% | ||
| $2.45M-34.6% | $3.75M-25.1% | $5.01M-69.0% | $16.18M+548% | -$3.61M-159% | ||
| $3.89M+4.7% | $3.72M-26.1% | $5.03M-26.8% | $6.88M+0.9% | $6.81M-0.1% | ||
| $43.19M-12.3% | $49.23M-9.0% | $54.07M-10.0% | $60.11M-0.1% | $60.16M-9.0% | ||
| -$8.22M— | —— | —— | $8.22M+129% | $3.6M+145% | ||
| $56K— | —— | —— | $1.11M+55,200% | $2K+100% | ||
| -$41.1M— | —— | —— | $6.42M+671% | -$1.12M-103% | ||
| $13.4M— | $0-100% | $10.16M+6.9% | $9.5M+1,752% | $513K— | ||
| -$2.88M+2.2% | -$2.94M— | —— | —— | $6.44M-2.2% | ||
| $13.35M-49.9% | $26.64M+27.5% | $20.89M+41.5% | $14.76M-37.6% | $23.67M-28.2% | ||
| -$1.49M-28.4% | -$1.16M+12.4% | -$1.32M-40.4% | -$941K+28.3% | -$1.31M+47.5% | ||
| $7.85M+162% | $3M-59.5% | $7.41M+724% | $900K-78.6% | $4.2M+600% | ||
| $5.69M-73.4% | $21.4M+677% | $2.75M-25.1% | $3.67M+283% | $960K-86.9% | ||
| $0— | —— | —— | $855K+63.2% | $524K— | ||
| —— | $523.5K0.0% | $523.5K0.0% | $523.5K0.0% | $523.5K— | ||
| —— | $18.74M0.0% | $18.74M0.0% | $18.74M0.0% | $18.74M+105,496% | ||
| $510K-35.8% | $795K— | —— | —— | $0— | ||
| $134.67M— | —— | —— | —— | $0— | ||
| $140.84M+103% | -$5.62B-320% | $2.55B+16,329% | $15.55M-93.4% | $235.53M+173% | ||
| $7.15M— | —— | $13.87M-44.3% | $24.89M+36,503% | $68K— | ||
| $1.35M— | —— | —— | —— | $1.7M— | ||
| $2.45M-34.6% | $3.75M-25.1% | $5.01M-69.0% | $16.18M+548% | -$3.61M-159% | ||
| $0— | —— | —— | —— | $4.81M— | ||
| -$34.92M-132% | $108.54M+2.3% | $106.15M+74.1% | $60.99M+1,160% | -$5.75M-106% | ||
| -$34.92M-132% | $108.54M+2.3% | $106.15M+74.1% | $60.99M+1,160% | -$5.75M-106% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amneal Pharmaceuticals, Inc. generate?
- Amneal Pharmaceuticals, Inc. (AMRX) generated $305.8M in operating cash flow over the trailing twelve months.
- What is Amneal Pharmaceuticals, Inc.'s free cash flow?
- After $65.1M of capital expenditures, Amneal Pharmaceuticals, Inc.'s free cash flow was $240.8M over the trailing twelve months, down 4.1% year over year.
- Where does Amneal Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
